Harrow (NASDAQ:HROW - Get Free Report)'s stock had its "sell (e+)" rating reissued by equities researchers at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.
Several other analysts have also recently issued reports on HROW. Zacks Research cut Harrow from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 12th. HC Wainwright restated a "buy" rating and set a $64.00 price objective on shares of Harrow in a research note on Monday, September 29th. BTIG Research restated a "buy" rating and set a $63.00 price objective on shares of Harrow in a research note on Wednesday, September 24th. B. Riley restated a "buy" rating and set a $74.00 price objective (up previously from $70.00) on shares of Harrow in a research note on Wednesday, October 1st. Finally, Lake Street Capital increased their price target on Harrow from $42.00 to $70.00 and gave the stock a "buy" rating in a research report on Monday, September 29th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $68.50.
Read Our Latest Report on HROW
Harrow Trading Down 5.2%
NASDAQ:HROW opened at $39.74 on Wednesday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. Harrow has a one year low of $20.85 and a one year high of $59.23. The business's 50-day simple moving average is $40.00 and its 200 day simple moving average is $32.48. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -158.96 and a beta of 0.27.
Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The firm had revenue of $63.74 million for the quarter, compared to analysts' expectations of $64.23 million. Harrow has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Harrow will post -0.53 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Harrow
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sonora Investment Management Group LLC grew its holdings in Harrow by 11.0% in the 3rd quarter. Sonora Investment Management Group LLC now owns 17,148 shares of the company's stock worth $826,000 after buying an additional 1,700 shares in the last quarter. Osaic Holdings Inc. grew its holdings in Harrow by 10.3% in the 2nd quarter. Osaic Holdings Inc. now owns 24,031 shares of the company's stock worth $734,000 after buying an additional 2,249 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Harrow by 345.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company's stock worth $103,000 after buying an additional 2,615 shares in the last quarter. Engineers Gate Manager LP grew its holdings in Harrow by 194.7% in the 2nd quarter. Engineers Gate Manager LP now owns 35,565 shares of the company's stock worth $1,086,000 after buying an additional 23,495 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Harrow by 266.8% in the 2nd quarter. Bank of America Corp DE now owns 213,448 shares of the company's stock worth $6,519,000 after buying an additional 155,258 shares in the last quarter. 72.76% of the stock is owned by institutional investors.
Harrow Company Profile
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
